Global Generic Injectables Market Overview:
The latest report published by IMARC Group, titled “Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the generic injectables market. The report also includes competitor and regional analysis, and contemporary advancements in the global market.
The global generic injectables market reached a value of US$ 40.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 65.4 Billion by 2027, exhibiting at a CAGR of 8.6% during 2022-2027.
Generic injectables consist of the same active ingredients as that of their branded counterparts. They also offer similar active therapeutic effects, strength, quality, performance, intended usage, and dosage. Injectables help in the easy transportation of drugs directly into the body in liquid form, which reduces the frequency of dosage administration without affecting the effectiveness of the treatment.
They also do not require extensive investments, resulting in limited price erosion and significantly high-profit margins for manufacturers.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global Generic Injectables Market Trends:
The global generic injectables market is primarily driven by their growing preference over oral counterparts as they are preferred by patients who are unable to take medicines by mouth and have poor intestinal absorption. Apart from this, governments across various countries are supporting the manufacturing of generic injectables to reduce the overall cost for healthcare providers and patients. Besides this, the increasing prevalence of chronic diseases like diabetes, cardiovascular disorders, and Alzheimer’s, especially among the geriatric population, and the rising shortage of drugs are significantly contributing to the market growth. Furthermore, several key players are engaging in acquisitions and focusing on research and development (R&D) activities to develop complex and differentiated products. For instance, Agila Injectables have been acquired by Mylan Inc. from Strides Arcolab Limited to expand their existing product portfolio.
Global Generic Injectables Market 2022-2027 Analysis and Segmentation:
Competitive Landscape with Key Players:
Hospira (Pfizer), Fresenius Kabi, Hikma, Sandoz (Novartis), Sagent, Sanofi and Baxter
Also, Read the Full Blog: List of the Top Generic Pharmaceuticals Injectables Companies Worldwide
Market Breakup by Therapeutic Area:
The report has segmented the market on the basis of therapeutic area as oncology, anaesthesia, anti-infectives, parenteral nutrition and cardiovascular. Currently, the oncology segment accounts for the majority of the market share.
Breakup by Container:
The report has segmented the market on the basis of container covering vials, ampoules, premix and prefilled syringes.
Market Breakup by Distribution Channel:
• Retail Pharmacy
Breakup by Region:
- North America
- Latin America
- Middle East and Africa
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800